Effects of octreotide on glycaemic control, glucose disposal, hepatic glucose production and counterregulatory hormones secretion in type 1 and type 2 insulin treated diabetic patients

M. Lunetta, M. Di Mauro, R. Le Moli, F. Nicoletti

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

We studied the effects of continuous subcutaneous infusion of octreotide (100 μ/day for 5 days) on glycaemic values, counterregulatory hormones secretion, hepatic glucose production (HGP) and glucose disposal during an euglycaemic clamp in 7 C-peptide-negative type 1 diabetic patients and 7 C- peptide positive insulin-treated type 2 diabetic patients. In type 1, but not type 2 diabetic patients, octreotide significantly reduced glycaemic values (P <0.005) and also diminished HGP during an euglycaemic clamp (P <0.005). However, insulin stimulated global glucose uptake remained unchanged. GH, glucagon, IGF-I, IGFBP-3 levels, were significantly lowered by octreotide in both type 1 and type 2 diabetic patients whereas cortisol and epinephrine remained unmodified. Moreover in type 2 diabetic patients both basal (P <0.05) and after-meal (P <0.01) C-peptide secretion was reduced by octreotide. These data point to different metabolic effects of octreotide in type 1 versus type 2 diabetic patients with the drug only being able to reduce glycaemic values and HGP in the former but not in the latter subjects. The failure of octreotide to diminish glycaemic values and HGP in type 2 diabetic patients in spite of its ability to lower GH and glucagon may probably depend on temporary blockage of residual endogenous insulin secretion induced by octreotide administration.

Original languageEnglish
Pages (from-to)81-89
Number of pages9
JournalDiabetes Research and Clinical Practice
Volume38
Issue number2
DOIs
Publication statusPublished - Nov 1997

Fingerprint

Octreotide
Hormones
Insulin
Glucose
Liver
C-Peptide
Glucose Clamp Technique
Glucagon
Subcutaneous Infusions
Insulin-Like Growth Factor Binding Protein 3
Insulin-Like Growth Factor I
Epinephrine
Meals
Hydrocortisone
Pharmaceutical Preparations

Keywords

  • Counterregulatory hormones
  • Hepatic glucose production
  • Octreotide
  • Type 1 diabetes
  • Type 2 diabetes

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

@article{384e311ad4f24cfc9bb1fdae2f832b61,
title = "Effects of octreotide on glycaemic control, glucose disposal, hepatic glucose production and counterregulatory hormones secretion in type 1 and type 2 insulin treated diabetic patients",
abstract = "We studied the effects of continuous subcutaneous infusion of octreotide (100 μ/day for 5 days) on glycaemic values, counterregulatory hormones secretion, hepatic glucose production (HGP) and glucose disposal during an euglycaemic clamp in 7 C-peptide-negative type 1 diabetic patients and 7 C- peptide positive insulin-treated type 2 diabetic patients. In type 1, but not type 2 diabetic patients, octreotide significantly reduced glycaemic values (P <0.005) and also diminished HGP during an euglycaemic clamp (P <0.005). However, insulin stimulated global glucose uptake remained unchanged. GH, glucagon, IGF-I, IGFBP-3 levels, were significantly lowered by octreotide in both type 1 and type 2 diabetic patients whereas cortisol and epinephrine remained unmodified. Moreover in type 2 diabetic patients both basal (P <0.05) and after-meal (P <0.01) C-peptide secretion was reduced by octreotide. These data point to different metabolic effects of octreotide in type 1 versus type 2 diabetic patients with the drug only being able to reduce glycaemic values and HGP in the former but not in the latter subjects. The failure of octreotide to diminish glycaemic values and HGP in type 2 diabetic patients in spite of its ability to lower GH and glucagon may probably depend on temporary blockage of residual endogenous insulin secretion induced by octreotide administration.",
keywords = "Counterregulatory hormones, Hepatic glucose production, Octreotide, Type 1 diabetes, Type 2 diabetes",
author = "M. Lunetta and {Di Mauro}, M. and {Le Moli}, R. and F. Nicoletti",
year = "1997",
month = "11",
doi = "10.1016/S0168-8227(97)00094-6",
language = "English",
volume = "38",
pages = "81--89",
journal = "Diabetes Research and Clinical Practice",
issn = "0168-8227",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Effects of octreotide on glycaemic control, glucose disposal, hepatic glucose production and counterregulatory hormones secretion in type 1 and type 2 insulin treated diabetic patients

AU - Lunetta, M.

AU - Di Mauro, M.

AU - Le Moli, R.

AU - Nicoletti, F.

PY - 1997/11

Y1 - 1997/11

N2 - We studied the effects of continuous subcutaneous infusion of octreotide (100 μ/day for 5 days) on glycaemic values, counterregulatory hormones secretion, hepatic glucose production (HGP) and glucose disposal during an euglycaemic clamp in 7 C-peptide-negative type 1 diabetic patients and 7 C- peptide positive insulin-treated type 2 diabetic patients. In type 1, but not type 2 diabetic patients, octreotide significantly reduced glycaemic values (P <0.005) and also diminished HGP during an euglycaemic clamp (P <0.005). However, insulin stimulated global glucose uptake remained unchanged. GH, glucagon, IGF-I, IGFBP-3 levels, were significantly lowered by octreotide in both type 1 and type 2 diabetic patients whereas cortisol and epinephrine remained unmodified. Moreover in type 2 diabetic patients both basal (P <0.05) and after-meal (P <0.01) C-peptide secretion was reduced by octreotide. These data point to different metabolic effects of octreotide in type 1 versus type 2 diabetic patients with the drug only being able to reduce glycaemic values and HGP in the former but not in the latter subjects. The failure of octreotide to diminish glycaemic values and HGP in type 2 diabetic patients in spite of its ability to lower GH and glucagon may probably depend on temporary blockage of residual endogenous insulin secretion induced by octreotide administration.

AB - We studied the effects of continuous subcutaneous infusion of octreotide (100 μ/day for 5 days) on glycaemic values, counterregulatory hormones secretion, hepatic glucose production (HGP) and glucose disposal during an euglycaemic clamp in 7 C-peptide-negative type 1 diabetic patients and 7 C- peptide positive insulin-treated type 2 diabetic patients. In type 1, but not type 2 diabetic patients, octreotide significantly reduced glycaemic values (P <0.005) and also diminished HGP during an euglycaemic clamp (P <0.005). However, insulin stimulated global glucose uptake remained unchanged. GH, glucagon, IGF-I, IGFBP-3 levels, were significantly lowered by octreotide in both type 1 and type 2 diabetic patients whereas cortisol and epinephrine remained unmodified. Moreover in type 2 diabetic patients both basal (P <0.05) and after-meal (P <0.01) C-peptide secretion was reduced by octreotide. These data point to different metabolic effects of octreotide in type 1 versus type 2 diabetic patients with the drug only being able to reduce glycaemic values and HGP in the former but not in the latter subjects. The failure of octreotide to diminish glycaemic values and HGP in type 2 diabetic patients in spite of its ability to lower GH and glucagon may probably depend on temporary blockage of residual endogenous insulin secretion induced by octreotide administration.

KW - Counterregulatory hormones

KW - Hepatic glucose production

KW - Octreotide

KW - Type 1 diabetes

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=0031426803&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031426803&partnerID=8YFLogxK

U2 - 10.1016/S0168-8227(97)00094-6

DO - 10.1016/S0168-8227(97)00094-6

M3 - Article

VL - 38

SP - 81

EP - 89

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

SN - 0168-8227

IS - 2

ER -